Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
Introduction: The predictive and prognostic implications of different KRAS mutation (KRASm) subtypes in metastatic NSCLC have not been clearly defined. We used a nationwide observational database to investigate whether KRASm subtypes differ in their association with survival in metastatic NSCLC trea...
Saved in:
Main Authors: | Lova Sun, MD, MSCE, Yunyun Zhou, PhD, Elizabeth A. Handorf, PhD, Hossein Borghaei, DO, Jessica Bauman, MD, Charu Aggarwal, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001255 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
by: Maximilian Kramer‐Drauberg, et al.
Published: (2025-02-01) -
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
by: Margaret Stalker, MD, et al.
Published: (2025-01-01) -
Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01) -
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
by: Arianna Marinello, MD, et al.
Published: (2025-03-01) -
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
by: Ismail M Meraz, et al.
Published: (2025-02-01)